[
    "ting the rupture of atherosclerotic plaques in a mammalian patient in need of such prevention comprising administering to said patient a compound that is capable of simultaneously binding or binding and activating PPAR\u03b1 and PPAR\u03b3 or concomitantly administering a selective PPAR\u03b1 agent with a selective PPAR\u03b3 agent in an amount that is effective to prevent the rupture of atherosclerotic plaques. The invention also encompasses a method for increasing atherosclerotic plaque stability in a mammalian patient in need thereof comprising administering to said patient a compound that is capable of simultaneously binding or binding and activating PPAR\u03b1 and PPAR\u03b3 or concomitantly administering a selective PPAR\u03b1 agent with a selective PPAR\u03b3 agent in an amount that is effective to increase plaque stability.</p>DETAILED DESCRIPTION OF THE INVENTION [0006] The present invention encompasses a method for preventing the rupture of atherosclerotic plaques in a mammalian patient in need of such prevention comprising administering to said patient a compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 or concomitantly administering a compound that selectively binds PPAR\u03b1 with a compound that selectively binds PPAR\u03b3 in an amount that is effective to prevent the rupture of atherosclerotic plaques. </p>[0007] Compounds that are capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 or \u201cdual ligands\u201d are defined as those compounds with half-maximal concentration potencies (IC<sub>50</sub>'s or KI's) for displacement of radioligand binding to hPPAR\u03b3 vs. hPPAR\u03b1 that differ by less than 30-fold as measured by the human PPAR\u03b1 and PPAR\u03b3 binding assays described below. All other compounds binding to PPAR\u03b1 and/or PPAR\u03b3 that fall outside this definition are considered compounds that selectively bind either PPAR\u03b1 or PPAR\u03b3 for purposes of this specification. </p>[0008] An embodiment of the invention encompasses administering the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3. </p>[0009] An embodiment of the invention encompasses the instant method wherein the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 has a half-maximal concentration potency (IC<sub>50</sub>or KI) for displacement of radioligand binding to hPPAR\u03b3 vs. hPPAR\u03b1 that differs by less than 20-fold as measured by the human PPAR\u03b1 and PPAR\u03b3 binding assays. Another embodiment is wherein the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 has a half-maximal concentration potency (IC<sub>50</sub>or KI) for displacement of radioligand binding to hPPAR\u03b3 vs. hPPAR\u03b1 that differs by less than 10-fold as measured by the human PPAR\u03b1 and PPAR\u03b3 binding assays. Another embodiment is wherein the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 has a half-maximal concentration potency (IC<sub>50</sub>or KI) for displacement of radioligand binding to hPPAR\u03b3 vs. hPPAR\u03b1 that differs by less than 5-fold as measured by the human PPAR\u03b1 and PPAR\u03b3 binding assays. Another embodiment is wherein the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 has a half-maximal concentration potency (IC<sub>50</sub>or KI) for displacement of radioligand binding to hPPAR\u03b3 vs. hPPAR\u03b1 differ by less than 2-fold as measured by the human PPAR\u03b1 and PPAR\u03b3 binding assays. </p>[0010] Another embodiment of the invention encompasses the instant method wherein the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 is orally active. For purposes of this specification, compounds that are orally active means compounds that produce a therapeutic response following oral ingestion of the compound. </p>[0011] Another embodiment of the invention encompasses the instant method wherein the compound that is capable of simultaneously binding PPAR\u03b1 and PPAR\u03b3 possesses a long duration of action. For purposes of this specification, compounds that possess a long duration of action means compounds that have a half-life equal to or exceeding about 1 hour. </p>[0012] The compounds of the present invention that can be used to prevent the rupture of atherosclerotic plaques have both PPAR\u03b1 and PPAR\u03b3 activity, which are defined in terms of PPAR agonism or in terms of binding to the PPAR receptors, partially displacing other compounds that are excellent PPAR ligands. </p>[0013] Another embodiment of the invention encompasses a method for preventing the rupture of atherosclerotic plaques in a mammalian patient in need of such prevention comprising administering to said patient a compound that is capable of simultaneously binding and activating PPAR\u03b1 and PPAR\u03b3 or concomitantly administering a compound that sele",
    "ay usually range from 5-20 uM. Similarly, methods involving the co-transfection of full-length PPAR\u03b3 or PPAR\u03b3 along with a relevant reporter gene into one of several mammalian (or yeast) cell types could be employed as an alternative method to identify compounds with both PPAR\u03b1 and PPAR\u03b3 agonist activity. </p>[0055] Cell-Free Co-Activator Association Assay </p>[0056] This assay measures the ability of compounds to promote the association of PPAR\u03b3 (or its isolated ligand binding domain) or PPAR\u03b1 (or its isolated ligand binding domain) with a protein (or portion of a protein) that is (or is derived from) a co-activator molecule such as Creb Binding Protein (CBP) or Steroid Receptor Coactivator 1 (SRC-1) and can be used to identify compounds with both PPAR\u03b1 and PPAR\u03b3 agonist activity. This assay is described in: Zhou G, Cummings R, Li Y, Mitra S, Wilkinson H, Elbrecht A, Hermes J D, Schaeffer J M, Smith R G, Moller D E. Nuclear receptors have distinct affinities for co-activators: characterization by fluorescence resonance energy transfer. Mol Endocrinol 1998 12:1594-1604, herein incorporated by reference in its entirety </p>[0057] Human PPAR\u03b1 and PPAR\u03b3 binding assays </p>[0058] An alternative to measuring agonist activity of compounds in cell-based transactivation assays or cell-free co-activator association assays is to determine that compounds can function as ligands by binding to both PPAR\u03b3 and PPAR\u03b1. Compounds with half-maximal concentration potencies (IC<sub>50</sub>'s or KI's) for displacement of radioligand binding to hPPAR\u03b3 vs. hPPAR\u03b1 that differ by less than 30-fold and preferably less than 10-fold can be considered as dual ligands. For these assays, the methods described below can be employed (as also described in: Berger J, Leibowitz M D, Doebber T W, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan C A, Hayes N S, Li Y, Tanen M, Ventre J, Wu M S, Berger G D, Mosley R, Marquis R, Santini C, Sahoo S P, Tolman R L, Smith R G, Moller D E. Novel peroxisome proliferator-activated receptor\u03b3 (PPAR\u03b3) and PPAR\u03b4 ligands produce distinct biological effects, 1999 J Biol Chem 274: 6718-6725, herein incorporated by reference in its entirety): </p>[0059] Human PPAR\u03b3<sub>2 </sub>and human PPAR\u03b1 were expressed as a GST-fusion protein in E. coli. The full length human cDNA for PPAR\u03b3<sub>2 </sub>was subcloned into the pGEX-2T expression vector (Pharmacia). The full length human cDNA for PPAR\u03b1 was subcloned into the pGEX-KT expression vector (Pharmacia). E. coli containing the respective plasmids were propagated, induced, and harvested by centrifugation. The resuspended pellet was broken in a French press and debris was removed by centrifugation at 12,000\u00d7g. Recombinant human PPAR receptors were purified by affinity chromatography on glutathione sepharose. After application to the column, and one wash, receptor was eluted with glutathione. Glycerol (10%) was added to stabilize the receptor and aliquots were stored at \u221280\u00b0 C. </p>[0060] For each assay, an aliquot of receptor was incubated in TEGM (10 mM Tris, pH 7.2, 1 mM EDTA, 10% glycerol, 7 \u03bcL/100 ml \u03b2-mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 5 \u03bcg/mL aprotinin, 2 \u03bcg/mL leupeptin, 2 \u03bcg/mL benzamidine and 0.5 mM PMSF) containing 0.1% non-fat dry milk and 10 nM [<sup>3</sup>H<sub>2</sub>]L-746,962, (21 Ci/mmole), \u00b1test compound. Assays were incubated for \u02dc16 hr at 4\u00b0 C. in a final volume of 150 \u03bcL. Unbound ligand was removed by incubation with 100 \u03bcL dextran/gelatin-coated charcoal, on ice, for 10 min. After centrifugation at 3000 rpm for 10 min at 4\u00b0 C., 50 \u03bcL of the supernatant fraction was counted in a Topcount. In this assay the KD for L-746,962 is \u22481 nM. </p>[0061] For a human PPAR\u03b1 binding assay, an aliquot of receptor was incubated in TEGM (10 mM Tris, pH 7.2, 1 mM EDTA, 10% glycerol, 7 \u03bcL/100 ml \u03b2-mercaptoethanol, 10 Na molybdate, 1 mM dithiothreitol, 5 \u03bc/mL aprotinin, 2 \u03bcg/mL leupeptin, 2 \u03bcg/mL benzamide and 0.5 mM PMSF) containing 0.1% non-fat dry milk and 5.0 nM [<sup>3</sup>H<sub>2</sub>]L-783483, \u00b1test compound. Assays were incubated for \u02dc16 hr at 4\u00b0 C. in a final volume of 150 \u03bcL. Unbound ligand was removed by incubation with 100 \u03bcL dextran/gelatin-coated charcoal, on ice, for \u02dc10 min. After centrifugation at 3000 rpm for 10 min at 4\u00b0 C., 50 \u03bcL of the supernatant fraction was counted in a Topcount. </p>[0062] Cell Proliferation Assay </p>[0063] This assay measures the ability of cells to convert MTS tetrazolium into formazan, using the AQ<sub>ueous </sub>cell proliferation assay kit (Promega, Madison, Wis.). This conversion is presumably accomplished by NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells. The assay is described in Shu, et al., Biochemical and Biophysical Research Communications, vol. 267, pp. 345-349 (2000). </p>[0064] MMP-9 ELISA </p>[0065] This assay is used for measuring the amount of MMP-9 secreted from cultured human monocytic THP-1 in response to lipopollysaccharide (LPS) stimulation. The assay is described in Shu, et al., Biochemical and Biophysical Research Communications, vol. 267, pp. 345-349 (2000). Cultured THP-1 cells were treated with PPAR\u03b1 and/or \u03b3 agonists for 2 hr at 37\u00b0 C. The cells we"
]